WestVac Biopharma Co., Ltd. (hereinafter referred to as "WestVac BioPharma"), founded by the research team headed by Professor WEI Yuquan, academician of Chinese Academy of Sciences and Director of the State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, is dedicated to the research, development and commercialization of vaccines and immunotherapies.
With the full support of governments at all levels, Sichuan University and West China Medical Center, WestVac BioPharma has been engaging in the industry chain for COVID-19 vaccine research and development from the onset of the pandemic. Affiliated to Sichuan University, West China Medical Center is the largest national medical center in western China. Its State Key Laboratory of Biotherapy is the only laboratory of its kind with the mandate of "Treating Critical Human Disease with Biotechnology". With the support from West China Medical Center and the State Key Laboratory of Biotherapy, WestVac Biopharma has established an accomplished R&D team of over 150 experts with multi-disciplinary background, including 13 Chang Jiang Scholars/Young Chang Jiang Scholars and 18 winners of the National Science Fund for Distinguished Young Scholars.
Driven by the "capital + innovation" model, role of market and strength in R&D mutually reinforce, thus accelerate the translation of vaccine development into market value. With the strong support of Chengdu Tianfu International Bio-town and continuous investment from influential shareholders such as Sichuan Development, Shanghai Pharma, CICC Capital, China Taiping, Haier Biomedical, WestVac Biological is now valued at more than US$1 billion and listed as a unicorn company in 2021.
In June 2021, the recombinant COVID-19 vaccine (Sf9 cell) developed by WestVac Biopharma completed the Phase I/II clinical trial with satisfactory immunogenicity indicated. At present, Phase III clinical trials are ongoing in Mexico, the Philippines, Indonesia, and Kenya. In August 2021, WestVac BioPharma and Nagasaki University jointly carried out the early phase clinical trial of the recombinant COVID-19 vaccine, which is the first clinical trial of a Chinese vaccine in Japan.
The Chengdu manufacturing base, located in Tianfu International Bio-town, has an annual capacity of 100 million doses of vaccine. A larger facility is under construction in Guangzhou with an expected annual capacity of 500 million doses.
WestVac Biopharma is committed to innovation for a world free of human disease!
